about   CII home   shop   checkout

 

Conference Menu

Current Event 

Overview
Part I: Therapeutics
Part II: Diagnostics
Register
Short Courses
Hotel & Travel
Part 1 PDF Download
Part 2 PDF Download
Sponsorship & Exhibits
Posters 
Press Pass 
Request Brochure 

Archives 


Download Event PDF
PAY Cover 


Co-Located Events 

Strategic Resource Management &Portfolio Management
November 5-7, 2012 


 Corporate Sponsors  

Analysis Group 

  

 

 

 


Corporate Support Sponsor 

Heron 


Media Partners 

Bio IT Word 

Bentham Science 

Biospace 

eCliniqua Logo 

 Genetic Engineering News 

 GenomeWeb 

HealthEconomics.com 

 nature 

  

 PharmaVoice 

 Science AAAS logo 

The Scientist 


Generating Evidence for Reimbursement Decisions: Therapeutics Conference - Day 1

Conference Proceeding CD Now Available
  • Speaker Presentations
  • Poster Abstracts
  • and More!
Archived Content

Day 1 | Day 2 

Monday, November 5

7:15-8:05am Conference Registration


INTEGRATING PAYERS’ REQUIREMENTS INTO PRODUCT DEVELOPMENT  

8:05 Chairperson’s Opening RemarksRandy H. Goodman, Ph.D., Manager, Pricing and Reimbursement Practice, Scientia Advisors 

8:15 Re-Imbursement, Non-Imbursement, Pre-Imbursement, Pro-Imbursement and Un-Imbursement: A Brave, New World

Allan Korn, M.D., CMO & Senior Vice President, Clinical Affairs, Blue Cross and Blue Shield Association

Generating evidence through clinical trials defines utility, not value.  Since most new (non me-too) pharmaceutical products create market monopolies, affordability is not foremost in the minds of drug developers.  Those who finance the delivery of care must, however, remain focused on it.  The evidence, and what we might do with it, will be deciding factors in determining the sustainability of the private-sector health care enterprise in the United States.  Possible future scenarios will be discussed.

9:00 Sanofi Aventis and Medco to Bring Payer View to R&D

Sheikh Usman Iqbal, M.D., MPH, MBA, Senior Director & Head, Oncology, Global Evidence & Value Development (EVD), Medical Affairs, Global R+D, Sanofi

Teresa K. Wilcox, Ph.D., Senior Research Leader, Health Economics, United BioSource Corporation

10:00 Coffee Break in Exhibit Hall

10:30 Real World Evidence Development: Providing Clarity to Decision-Makers

Marcus Wilson, Pharm.D., President, HealthCore, Inc.

Rising healthcare costs coupled with disappointing outcomes of care are driving demand for more evidence of value and safety derived from real world experience. In addition, with the rapid proliferation of HIT deployment, electronic healthcare data are becoming more available. This presentation will focus on recent trends on real world evidence development and efforts to use these data for research.

11:00 What Are the Key Data Needs of Payers: A Country (US) Perspective

Amy Guo, Ph.D., Head US HEOR, Novartis Oncology

The US payer landscape is characterized by many players, with different evidentiary requirement and is rapidly evolving. The data required for regulatory approval may not be sufficient for reimbursement. The speaker will discuss the data needs of public and private payers, as well as the data needs of other key players with impact on payers. The speaker will also discuss potential actions before and after a product launch to include country input into the global clinical development program.

11:30 Policies Surrounding the Role of Government in Pharmaceutical Access and Reimbursement

Robert Popovian, Pharm.D., MS, Senior Director, Advocacy and Professional Relations, US Public Affairs, Pfizer, Inc.

Digital Infuzion12:00pm Advancing Real World Evidence with Health IT InnovationChristopher Jones, Ph.D., Vice President, Health IT Strategy, Digital InfuzionAs the life sciences industry balances simultaneous challenges of cost reduction and R & D expense with new medical advances such as gene sequencing, there are risks and opportunities emerging in real world, data-driven knowledge. This talk will look at some of the new models and health IT innovations that can help re-invent notions of "evidence" beyond RCT and other traditional publication methods.


GENERATING REAL-WORLD DATA 

1:25 Chairperson’s Opening RemarksLarry Z. Liu, M.D., Ph.D., Senior Director, Global Health Economics & Outcomes Research Market Access, Pfizer Primary Care BU 

1:30 Accelerating Real World Data into the Development Process

David Recker, M.D., Vice President, Clinical Development, Takeda

While the traditional approach to drug development has been to follow accepted scientific practice of holding as many variables as possible constant and then assessing the variable of interest, RCT’s need to better incorporate the variability associated with the real world while trying to maintain scientific validity as much as possible.

2:00 The Learning Healthcare System: Producing Evidence in the Course of Delivering Usual Care

Louis Fiore, M.D., Executive Director, Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), Department of Veterans Affairs

Clinical Effectiveness Research that is research designed specifically to inform healthcare systems (including comparative effectiveness and cost effectiveness research), uses the healthcare delivery system itself as its own natural laboratory. This presentation will explore embedding clinical effectiveness research in the healthcare system using the Department of Veterans Affairs ‘Point-of-Care Research Program’ as a model.

2:30 Use of Real World Data for Comparative Effectiveness Research: An Example of Lipitor Studies

Larry Z. Liu, M.D., Ph.D., Senior Director, Global Health Economics & Outcomes Research Market Access, Pfizer Primary Care BU

Lipitor is probably the most used medication by millions of patients across the globe. Its rich, real world experience has offered great opportunity to conduct comparative effectiveness research as required for access and reimbursement decisions.

3:00 Panel Discussion: Clinical Trials to Meet Reimbursement Evidence Platform (Sponsorship Opportunity Available)Moderator: Douglas J. Moeller M.D., Medical Director, Claims Performance & Advanced Diagnostics Management, McKesson Health Solutions

  • Do conventional clinical trials still makes sense for therapeutics? For diagnostics?
  • Clinical Validity (the treatment works) vs clinical utility (how good is good enough)?
  • Are peer reviewed journals still the Gold Standard or does other evidence pass the test?
  • How do we properly publicize the evidence that we have?
  • Can concurrent clinical trials be developed via that Internet, for special interest groups (e.g. muscular dystrophy)?
    Panelists:
    David Recker, M.D., Vice President, Clinical Development, Takeda
    Larry Z. Liu, M.D., Ph.D., Senior Director, Global Health Economics & Outcomes Research Market Access, Pfizer Primary Care BU
    Sheikh Usman Iqbal, M.D., MPH, MBA, Senior Director & Head, Oncology, Global EVD, Medical Affairs, Sanofi

3:45 Refreshment Break in Exhibit Hall

4:15 Interactive Breakout Discussions

Concurrent breakout discussion groups are interactive, guided discussions hosted by a facilitator or set of co-facilitators to discuss some of the key issues presented earlier in the day’s sessions. Delegates will join a table of interest to them and become an active part of the discussion at hand.
Topics:
Working with Government Agencies on Achieving Your Reimbursement GoalsRobert Popovian, Pharm.D., MS, Senior Director, Advocacy and Professional Relations, US Public Affairs, Pfizer, Inc.Use of Real World Data for Comparative Effectiveness ResearchLarry Z. Liu, M.D., Ph.D., Senior Director, Global Health Economics & Outcomes Research Market Access, Pfizer Primary Care BU
A Payer and a Pharma Company: is Collaboration Possible?S. Rebecca Chiappinelli, RPh, Director, Business Development, Prospective Effectiveness Research & HEOR, HealthCore, Inc.
 

5:15 Welcome Reception in Exhibit Hall

6:00 End of Day


6:00 - 9:00 pm DINNER SHORT COURSE*

Systems for Evidence Creation and Evidence Dossiers for Payers

Randy H. Goodman, Ph.D., Manager, Pricing and Reimbursement Practice, Scientia Advisors
Grant Bagley, M.D., J.D., HillCo Partners
This course is designed to provide participants an overview of the topic of effective evidence generation, dossier production, targeted evidence materials, evidence submission and dissemination to key stakeholders for successful product commercialization in North America.
The presentation will convene basic concepts and fundamental understanding of the key terminology and issues involved in evidence review, market access, product pricing, and coverage policy decisions as well as the emerging principles of demonstrating high medical-value and clinical comparative effectiveness.
Areas to be discussed will include the various methods and tools to document unique product value(s); role of the patient stratification (e.g., differential clinical benefit, sub-classification, pharmacogenomics, etc.) and the attributes of evidence platforms that can assist with coverage and payment decisions.
Finally, in the context of health care and payment reform a review of the wider policy issues will be addressed.
 

* Separate registration required



Overview | Day 1 | Day 2